Antibiotic use is associated with SJ syndrome and toxic epidermal necrosis, with sulfonamides being the most common culprits.

Published Date: 17 Feb 2023

Antibiotic use linked to SJ syndrome and toxic epidermal necrosis, sulfonamides are worst culprits in new study...

Read Full News

Latest News

Make the Diagnosis: This Cyst Is Asymptomatic. Is It a Problem?

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Targeted Oral Drug Plus UV Therapy May Help in Extensive Vitiligo

Positive signs in phase II test

Novel Drug Eases Disease Activity in Dermatomyositis

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Biomarker May Flag Humira Responders in Hidradenitis Suppurativa

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

What Botox Teaches Us About Serendipity in Clinical Encounters

Don't forget the power of a strong doctor-patient relationship

Make the Diagnosis: Are Her Nail Symptoms Part of a Larger Picture?

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

Todays Updates

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Todays Updates

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

FDA Awards Accelerated Approval to Sibeprenlimab in IgA Nephropathy

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Latest News

A 67-year-old man visited the doctor for a cyst-like lesion that developed on his face 3 months prior.

Positive signs in phase II test

Dazukibart targets specific molecular pathology of chronic systemic autoimmune disease

Patients' C-reactive protein levels also reflect significantly higher BMI and disease severity

Don't forget the power of a strong doctor-patient relationship

A 62-year-old woman visited her doctor about thick, crumbling, discolored toenails that developed over many months. Can you diagnose the patient?

News All Time

Novel Drug for Chronic Inducible Urticaria Delivers in Mid-Stage Trial

Impressive responses with barzolvolimab in cold urticaria, symptomatic dermographism

Dupilumab Proves Effective in Chronic Spontaneous Urticaria

Significant reduction in hives and itch in antihistamine-resistant patients

50 Years After City Halted Prison Medical Testing, Families Seek Reparations

"No amount of money can replace what was done to me," said one former prisoner

Make the Diagnosis: She Feels Fine, But Why Do Her Fingers Look Like This?

A 38-year-old woman visited her doctor about itchy, raised spots that developed on her fingers 5 days prior. Can you diagnose the patient?

A Look at Kamala Harris' Medical History

Veep in "excellent health," doctor says, with history that includes seasonal allergies, urticaria

Selective Role for Single-Agent Ipilimumab After Anti-PD-1 Failure in Melanoma

Two-year survival in second line for patients with BRAF/NRAS wild-type tumors

Acne Treatments Taken Right Off the Shelf Had High Levels of Benzene

Study findings suggest cold storage may prevent breakdown into carcinogen

Make the Diagnosis: It’s Ugly, and It Hurts. What the Heck Is It?

A 29-year-old woman visited the doctor for a painful rash that developed on her arm 1 day after working on a landscaping project that involved pulling weeds under intense sunlight. Can you diagnose the patient?

Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial Finds

But only a minority achieved minimal disease activity within 16 weeks

Lebrikizumab Wins FDA Approval for Eczema

38% of patients treated with IL-13 blocker achieved clear or almost-clear skin at 16 weeks

Higher Steroid Dose for ICI Toxicity Harms Cancer Survival, Analysis Suggests

More data for discussion of controversial association between steroids, immunotherapy

Stopping JAK Inhibitor for Severe Alopecia Areata Led to Hair Loss

Long-term maintenance therapy is necessary, researchers caution

IL-31 Drug for Itchy Nodular Skin Disease Gets Thumbs Up From FDA

Nemolizumab significantly improved itch, nodules, and sleep disturbance at 16 weeks

IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL

New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients

Psoriasis Control Maintained Long Term With Extended Dosing Interval of Guselkumab

More than 90% of patients met response criteria at 68 weeks with 8- or 16-week dosing

Common Antibiotics Linked With Serious Skin Reactions in Older Adults

Sulfonamides and cephalosporins the worst offenders, study finds

Recommended News For You

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

A novel test shows promise for finding cervical adenocarcinoma, which is difficult to find.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing

Study finds higher breast cancer rates in areas with more air pollution

Recommended Articles For You

The Importance of Early Detection in Angiosarcoma: A Story of Survival  

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies 

Cancer Vaccines In India: The Latest Hope In The Fight Against Disease 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A retrospective study examined the role of CA 19-9 and CEA in duodenal adenocarcinoma prognosis.

2.

Clinical Evidence Shows Venetoclax Combo Is Safe and Effective in AML Patients 80 Years of Age and Up.

3.

Trial Questions Role of Dual Immunotherapy in First-Line NSCLC

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Dementia-like protein buildup found in pancreas cells before cancer develops

1.

The Importance of Having a Quick and Effective Heparin Antidote 

2.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

3.

AI Revolutionizes Immunotherapy: Unveiling Biomarkers with Machine Intelligence

4.

Revolutionizing Cancer Treatment with Darzalex: How an Innovative Drug is Transforming Lives

5.

Obesity is a major risk factor for cancer

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

2.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

3.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

4.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

5.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot